HK1159693A1 - Production of closed linear dna - Google Patents

Production of closed linear dna

Info

Publication number
HK1159693A1
HK1159693A1 HK12100003.1A HK12100003A HK1159693A1 HK 1159693 A1 HK1159693 A1 HK 1159693A1 HK 12100003 A HK12100003 A HK 12100003A HK 1159693 A1 HK1159693 A1 HK 1159693A1
Authority
HK
Hong Kong
Prior art keywords
production
linear dna
closed linear
closed
dna
Prior art date
Application number
HK12100003.1A
Other languages
English (en)
Inventor
Vanessa Hill
Original Assignee
Touchlight Genetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40469378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1159693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Touchlight Genetics Ltd filed Critical Touchlight Genetics Ltd
Publication of HK1159693A1 publication Critical patent/HK1159693A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6846—Common amplification features
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK12100003.1A 2009-01-30 2012-01-03 Production of closed linear dna HK1159693A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0901593.4A GB0901593D0 (en) 2009-01-30 2009-01-30 Production of closed linear DNA
PCT/GB2010/000165 WO2010086626A1 (en) 2009-01-30 2010-02-01 Production of closed linear dna

Publications (1)

Publication Number Publication Date
HK1159693A1 true HK1159693A1 (en) 2012-08-03

Family

ID=40469378

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100003.1A HK1159693A1 (en) 2009-01-30 2012-01-03 Production of closed linear dna

Country Status (20)

Country Link
US (4) US9109250B2 (pt)
EP (3) EP2612925B1 (pt)
JP (2) JP2012516147A (pt)
KR (1) KR101926662B1 (pt)
CN (2) CN102301010B (pt)
AU (1) AU2010209532B2 (pt)
BR (1) BRPI1005683B1 (pt)
CA (1) CA2751130C (pt)
DK (2) DK2391731T3 (pt)
EA (1) EA021069B1 (pt)
ES (2) ES2749629T3 (pt)
GB (1) GB0901593D0 (pt)
HK (1) HK1159693A1 (pt)
IL (1) IL213930A (pt)
LT (1) LT3150722T (pt)
MX (1) MX2011007937A (pt)
NZ (1) NZ594004A (pt)
SG (1) SG173102A1 (pt)
WO (1) WO2010086626A1 (pt)
ZA (1) ZA201105013B (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017060650A1 (fr) 2015-10-08 2017-04-13 Jean-Marc Limacher Composition anti-tumorale
CN107614675A (zh) * 2015-07-16 2018-01-19 香港科技大学 用于单分子dna分析的纳米通道的动态形成

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351294B8 (es) * 2009-07-02 2012-06-06 Consejo Superior De Investigaciones Científicas (Csic) Metodo para la replicación, amplificación, o secuenciación de un adn molde.
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US9290800B2 (en) 2013-03-15 2016-03-22 Pacific Biosciences Of California, Inc. Targeted rolling circle amplification
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
AU2016375021B2 (en) 2015-12-22 2022-02-03 CureVac SE Method for producing RNA molecule compositions
RU2616279C1 (ru) * 2015-12-28 2017-04-13 Федеральное государственное бюджетное учреждение науки Институт биохимии и генетики Уфимского научного центра Российской академии наук (ИБГ УНЦ РАН) Способ получения маркерных лестниц для гель-электрофоретического определения размеров фрагментов нуклеиновых кислот
US10077459B2 (en) 2016-05-04 2018-09-18 General Electric Company Cell-free protein expression using rolling circle amplification product
LT3500682T (lt) * 2016-08-16 2020-10-26 Touchlight IP Limited Uždarytos linijinės dnr gamyba
TW201936201A (zh) * 2017-12-14 2019-09-16 美商堅固生物科技公司 基因之非病毒生產及遞送
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
CN109971825B (zh) * 2017-12-28 2020-11-10 南京金斯瑞生物科技有限公司 快速制备桑格测序模板的方法
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
EP3810782A2 (en) 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
WO2020092904A1 (en) * 2018-11-02 2020-05-07 Nikegen, Llc Recombinant parvoviral vectors and method of making and use thereof
EP3986562A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
CA3143634A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
MA56523A (fr) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
WO2020255014A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Recombinant interleukin 12 construct and uses thereof
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
CA3143679A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
WO2020255063A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
WO2020255062A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
EP3792367A1 (en) 2019-09-11 2021-03-17 Universität Bielefeld Method for the production of raav and method for the in vitro generation of genetically engineered, linear, single-stranded nucleic acid fragments containing itr sequences flanking a gene of interest
TW202124722A (zh) 2019-09-18 2021-07-01 美商英特佳樂帝克醫療公司 合成dna載體及其使用方法
GB201915163D0 (en) 2019-10-18 2019-12-04 Univ Southampton Cancer vaccine
JP2023506631A (ja) 2019-12-20 2023-02-17 キージーン ナムローゼ フェンノートシャップ 共有結合で閉端された核酸分子末端を使用したｎｇｓライブラリー調製
JP2023510590A (ja) * 2020-01-17 2023-03-14 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 組換えａａｖの産生
GB202007428D0 (en) 2020-05-19 2020-07-01 Fabricnano Ltd Polynucleotide synthesis
AU2021289600A1 (en) 2020-06-12 2023-01-19 University Of Rochester Encoding and expression of ACE-tRNAs
KR20230058081A (ko) 2020-08-26 2023-05-02 스캔셀 리미티드 인간 IgG1의 변형된 FC 영역과 적어도 하나의 이종 항원을 포함하는 폴리펩티드를 암호화하는 핵산
WO2022074058A1 (en) 2020-10-06 2022-04-14 Keygene N.V. Targeted sequence addition
EP4317424A1 (en) 2021-03-29 2024-02-07 Kaneka Corporation Vector, method for preparing linear covalent bond closed dna using same, parvovirus vector preparation method, and parvovirus vector producing cell
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
IL308705A (en) 2021-06-08 2024-01-01 Touchlight Ip Ltd LENTIVIRAL vector
AU2022299552A1 (en) 2021-06-25 2024-01-04 Oxford Biomedica (Us) Llc Adeno-associated virus packaging systems
CA3226725A1 (en) 2021-07-13 2023-01-19 Stonehaven Incubate AG Composition and uses thereof
ES2947031T6 (pt) 2021-07-30 2023-08-02
JP2024533311A (ja) 2021-09-08 2024-09-12 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ゲノムを調節するための方法及び組成物
GB202114105D0 (en) 2021-10-01 2021-11-17 Fabricnano Ltd Nucleotide synthesis
US20230323395A1 (en) 2021-12-15 2023-10-12 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus
AU2022422134A1 (en) * 2021-12-23 2024-07-04 Generation Bio Co. Scalable and high-purity cell-free synthesis of closed-ended dna vectors
CN114561372B (zh) * 2022-04-27 2022-07-26 南京巨匠生物科技有限公司 Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌
EP4293101A1 (en) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Reactor with temperature control and method of using the same
WO2024032690A1 (zh) * 2022-08-10 2024-02-15 江苏金斯瑞蓬勃生物科技有限公司 线性闭合dna的制备方法及该方法所用质粒
WO2024069549A1 (en) 2022-09-29 2024-04-04 Touchlight Aquaculture Limited Vaccine construct and uses thereof
WO2024094793A1 (en) 2022-11-02 2024-05-10 4Basebio, S.L.U. Purification of linear dna products
EP4365303A1 (en) 2022-11-02 2024-05-08 4basebio, S.L.U. Purification of linear dna products
WO2024121354A1 (en) 2022-12-08 2024-06-13 Keygene N.V. Duplex sequencing with covalently closed dna ends
WO2024132094A1 (en) 2022-12-19 2024-06-27 Thermo Fisher Scientific Geneart Gmbh Retrieval of sequence-verified nucleic acid molecules
EP4410995A1 (en) 2023-02-01 2024-08-07 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases and methods for the production thereof
EP4410992A1 (en) 2023-02-01 2024-08-07 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases and methods for the production thereof
WO2024197081A1 (en) 2023-03-20 2024-09-26 Hc Bioscience, Inc. Minimally-sized dna threads for trna therapy
CN116606834A (zh) * 2023-04-10 2023-08-18 天津中合基因科技有限公司 多种具有切割连接活性的原端酶及其应用
US11981936B1 (en) 2023-09-29 2024-05-14 New England Biolabs, Inc. TelA variants, compositions, and methods

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン，インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
US6953676B1 (en) 1992-05-01 2005-10-11 Trustees Of The University Of Pennsylvania Mesoscale polynucleotide amplification device and method
WO1994003624A1 (en) 1992-08-04 1994-02-17 Auerbach Jeffrey I Methods for the isothermal amplification of nucleic acid molecules
US5714320A (en) 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
EP0636413B1 (en) 1993-07-28 2001-11-14 PE Corporation (NY) Nucleic acid amplification reaction apparatus and method
FR2732971B1 (fr) 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
AU714486B2 (en) 1995-11-21 2000-01-06 Yale University Unimolecular segment amplification and detection
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
JPH10234399A (ja) 1997-02-28 1998-09-08 Shinkinrui Kinou Kaihatsu Kenkyusho:Kk ピシウム属菌検出用の核酸配列
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6054274A (en) * 1997-11-12 2000-04-25 Hewlett-Packard Company Method of amplifying the signal of target nucleic acid sequence analyte
CA2312102C (en) 1997-12-24 2007-09-04 Cepheid Integrated fluid manipulation cartridge
ATE346158T1 (de) 1998-01-09 2006-12-15 Univ Utah Res Found Verfahren zur in vitro amplifikation zirkulärer dna
DE19826758C1 (de) 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
EP1114184A2 (en) 1998-09-15 2001-07-11 Yale University Molecular cloning using rolling circle amplification
DE50010240D1 (de) * 1999-07-08 2005-06-09 Mologen Forschungs Entwicklung Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
US20040241651A1 (en) 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
GB0018120D0 (en) 2000-07-24 2000-09-13 Fermentas Ab Nuclease
US6977148B2 (en) 2001-10-15 2005-12-20 Qiagen Gmbh Multiple displacement amplification
US20030077611A1 (en) 2001-10-24 2003-04-24 Sention Methods and systems for dynamic gene expression profiling
US20030170693A1 (en) 2001-12-21 2003-09-11 George Chaconas Assay for identifying modulators of Borrelia telomere resolvase
US7081339B2 (en) 2002-04-12 2006-07-25 Primera Biosystems, Inc. Methods for variation detection
US20040175719A1 (en) 2002-07-12 2004-09-09 Affymetrix, Inc. Synthetic tag genes
US20040022764A1 (en) 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
DE50304603D1 (de) * 2002-09-23 2006-09-21 Mologen Ag Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
US7955795B2 (en) 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
WO2004065582A2 (en) 2003-01-15 2004-08-05 Dana-Farber Cancer Institute, Inc. Amplification of dna in a hairpin structure, and applications
WO2004074503A2 (en) 2003-02-21 2004-09-02 Hoser Mark J Nucleic acid sequencing methods, kits and reagents
JP2007512020A (ja) 2003-11-26 2007-05-17 エッペンドルフ アクチェンゲゼルシャフト 染色体外核酸のインビトロ増幅のための方法及び組成物
US20080305142A1 (en) 2004-12-11 2008-12-11 Cytogenix, Inc. Cell Free Biosynthesis of High-Quality Nucleic Acid and Uses Thereof
EP1871897B1 (en) 2005-04-12 2010-09-29 Olink AB Methods for production of oligonucleotides
CN101213311B (zh) 2005-04-29 2013-02-13 合成基因组股份有限公司 利用滚环扩增扩增和克隆单个dna分子
EP2377929A1 (en) 2005-10-06 2011-10-19 Lucigen Corporation Thermostable viral polymerases and methods of use
US9029134B2 (en) * 2006-01-12 2015-05-12 Lucigen Corporation Linear vectors, host cells and cloning methods
CA2713101C (en) 2006-10-06 2016-09-13 Vandalia Research, Inc. Method for a continuous rapid thermal cycle system
WO2008151023A2 (en) * 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US8921072B2 (en) * 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US9114399B2 (en) 2010-08-31 2015-08-25 Canon U.S. Life Sciences, Inc. System and method for serial processing of multiple nucleic acid assays
EP2692870A1 (en) 2012-08-03 2014-02-05 Alacris Theranostics GmbH Method for nucleic acid amplification
KR102014989B1 (ko) 2013-04-15 2019-08-27 삼성전자주식회사 폴리뉴클레오티드 및 그의 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107614675A (zh) * 2015-07-16 2018-01-19 香港科技大学 用于单分子dna分析的纳米通道的动态形成
WO2017060650A1 (fr) 2015-10-08 2017-04-13 Jean-Marc Limacher Composition anti-tumorale

Also Published As

Publication number Publication date
GB0901593D0 (en) 2009-03-11
EA201101141A1 (ru) 2012-05-30
US20190203282A1 (en) 2019-07-04
US9109250B2 (en) 2015-08-18
EP2612925B1 (en) 2016-11-30
WO2010086626A1 (en) 2010-08-05
SG173102A1 (en) 2011-08-29
CN102301010B (zh) 2015-07-08
AU2010209532B2 (en) 2015-06-25
BRPI1005683B1 (pt) 2019-11-12
CA2751130C (en) 2018-03-06
EP2612925A1 (en) 2013-07-10
DK3150722T3 (da) 2019-12-16
ES2400890T3 (es) 2013-04-15
AU2010209532A1 (en) 2011-07-28
NZ594004A (en) 2013-01-25
DK2391731T3 (da) 2013-04-22
EP3150722A1 (en) 2017-04-05
CN102301010A (zh) 2011-12-28
EP2391731A1 (en) 2011-12-07
US20220372565A1 (en) 2022-11-24
BRPI1005683A2 (pt) 2019-04-02
EP3150722B1 (en) 2019-09-11
MX2011007937A (es) 2011-08-17
EP2391731B1 (en) 2013-01-23
CA2751130A1 (en) 2010-08-05
JP2016047049A (ja) 2016-04-07
LT3150722T (lt) 2019-12-10
KR101926662B1 (ko) 2018-12-07
KR20110107846A (ko) 2011-10-04
EA021069B1 (ru) 2015-03-31
ZA201105013B (en) 2013-03-27
ES2749629T3 (es) 2020-03-23
US11384388B2 (en) 2022-07-12
IL213930A0 (en) 2011-07-31
CN104911177A (zh) 2015-09-16
US20150329902A1 (en) 2015-11-19
JP6454243B2 (ja) 2019-01-16
IL213930A (en) 2014-08-31
US20120282283A1 (en) 2012-11-08
JP2012516147A (ja) 2012-07-19

Similar Documents

Publication Publication Date Title
HK1159693A1 (en) Production of closed linear dna
GB201013153D0 (en) Primer for production of closed linear DNA
ZA201202407B (en) Photobioreactor
EP2490770A4 (en) FAST MANUFACTURE OF CUSTOM MADE MASKS
PL2502173T3 (pl) Projektowanie cząsteczek
GB201118187D0 (en) Photobioreactor
EP2438246A4 (en) CONSTRUCTION ASPECTS
PT2435578T (pt) Produção biotecnológica de condroitina
EP2484355A4 (en) ACCELERATION COMPOSITION FOR PRODUCTION OF LAMININ-332
GB201011476D0 (en) Controlled production of biomaterial
IL216857A0 (en) Production of algae
EP2561085A4 (en) PRODUCTION BASED ON NONULOSONATE CELLS
EP2430180A4 (en) gene synthesis
ZA201202509B (en) Production of hydrocarbons
GB2473518B (en) Booklet production
GB0914589D0 (en) Novel compounds and methods for their production
GB2458818B (en) Production of butanol
GB0910401D0 (en) Production of nanoparticles
EP2440415A4 (en) MATRIX ALIGNMENT
GB0904540D0 (en) Novel compounds and methods for their production
GB0917817D0 (en) Novel compounds and methods for their production
GB0816419D0 (en) Production of hydroelecticity
GB0904542D0 (en) Novel compounds and methods for their production
GB0917816D0 (en) Novel compounds and methods for their production
GB0903809D0 (en) Production of protein